GLP-1 receptor agonists (semaglutide, liraglutide) produce meaningful weight loss and cardiometabolic benefits in adolescents with obesity, but the authors argue that weight reduction during peak bone and muscle accrual windows may blunt attainment of maximum musculoskeletal capacity—a deficit that could amplify frailty risk decades later. The piece advocates for mandatory co-prescription of resistance training, weight-bearing activity, and protein-adequate nutrition as non-negotiable companions to pharmacotherapy.
This perspective arrives at a critical moment. Adult GLP-1 data consistently show 25–40% of weight lost on semaglutide is lean mass, a proportion that alarms even geriatric researchers. In adolescents, the stakes are compounded: bone mineral density and muscle fiber recruitment patterns established between ages 10–18 largely define lifetime skeletal reserve. Failing to hit peak bone mass is among the strongest modifiable predictors of osteoporotic fracture in later life—an outcome that typically emerges 40–50 years post-adolescence, long after today's pediatric GLP-1 cohorts are out of clinical view.
The piece's core limitation is that it offers expert opinion, not new data. No longitudinal DXA scans, muscle biopsy findings, or fracture incidence figures are presented. Importantly, the counterfactual matters: severe adolescent obesity itself suppresses bone quality and muscle function, so net musculoskeletal harm from GLP-1s is genuinely uncertain. Still, the call for structured resistance training protocols embedded within pediatric obesity pharmacotherapy programs is both clinically sound and underserved in current guidelines—making this a timely, if incremental, contribution.
